Shares of Repligen Co. (NASDAQ:RGEN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going ...

Learn more about whether Medpace Holdings, Inc. or Repligen Corporation is a better investment based on AAII's A+ Investor ...

Signaturefd LLC lifted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 172.2% in the 4th quarter, according to ...

Repligen’s strong growth and bioprocessing expansion position it for success. Find out why RGEN stock is a Buy, with a $175 ...

Evercore ISI initiated coverage of Repligen (RGEN) with an In Line rating and $155 price target The firm sees the company as a high quality ...

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Repligen (NASDAQ:RGEN), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus ...

On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.